Compare Cytokinetics Inc (CYTK) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Futu Holdings Ltd — how do they compare? Cytokinetics Inc trades at $62.67 (market cap $8.62B), while Futu Holdings Ltd trades at $113.49 (market cap $15.25B). The key difference: Futu Holdings Ltd is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.39% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Futu Holdings Ltd for 34 Days on average.
| CYTK | FUTU | |
|---|---|---|
Market Cap | $8.62B | $15.25B |
Volume | 2,594,626 | 812,567 |
Sector | Health | Financials |
52-Week High | $87.26 | $199.04 |
52-Week Low | $54.76 | $89.76 |
Typical Hold Time | 19 Days | 34 Days |
Enterprise Value | $8.72B | $15.59B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Futu Holdings trades at $109.68, down 3.12% today amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.86, net income margin of 42.92%, and robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Recent news includes Moomoo's partnership with X's Cashtag program and a class action lawsuit deadline on August 25, 2026.
The outlook is mixed: strong profitability and analyst upside targets near 33% contrast with legal risks and technical weakness. Key risks include lawsuit outcomes and market volatility, while growth drivers are overseas expansion and trading platform adoption. Investors face a balance of high returns potential against significant headline risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
